Evoking neuronal activity to improve the lives of Alzheimer’s patients
.webp)
Spectris
We are leading a novel category of non-invasive neuroprotective therapy in Alzheimer’s disease with Spectris
Developed with a novel mechanism of action
Research shows that Alzheimer's patients have disrupted neuronal activity in the brain1. We're advancing a new way of treating Alzheimer's disease by delivering non-invasive audiovisual stimulation to engage this disrupted activity.
.svg)
Promising results from our feasibility study
In our OVERTURE feasibility study significant slowing of disease progression was observed among treated patients through the preservation of cognition, daily function, and whole brain volume.
Designed to fit into patient’s lives
Patients receive our non-invasive Spectris therapy from the comfort of their home for one hour each day.
Why do the brain's electrical activities matter?
Neurons communicate through electric signals, creating rhythmic brain activity known as "brain waves." When groups of neurons start firing at the same time, distinct brain waves form at various ranges. One such range is gamma waves, which play an important role in learning and memory. In Alzheimer’s patients, gamma waves are altered, indicating impairment in normal brain function.1
How does our treatment work?
Spectris AD is designed to evoke gamma wave activity through non-invasive visual and auditory stimulation. In our OVERTURE feasibility study, it demonstrated slowing of cognitive and functional decline and preservation of brain volume among treated Alzheimer's patients.
.webp)
Cognito's headset design concept
.webp)
Spectris AD received FDA Breakthrough Device Designation for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease, and we are expanding our approach to many other indications.
.svg)
Click to enlarge
It all started with a breakthrough from leading MIT neuroscientists
Press, publications & announcements
March 5, 2026
Cognito Lands $105m for Sensory Stimulation Alzheimer’s Therapy
March 5, 2026
Big Backing for Brain Health: Cognito Therapeutics Closes $105m Series C
March 5, 2026
Cognito Therapeutics Closes Oversubscribed $105M Series C
.svg)
March 5, 2026
Cognito Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease
February 16, 2026
Can Flickering Lights and Sound Slow Alzheimer’s?
Citations
1Traikapi A and Konstantinou N (2021) Gamma Oscillations in Alzheimer’s Disease and Their Potential Therapeutic Role. Front. Syst. Neurosci. 15:782399. doi: 10.3389/fnsys.2021.782399